Go back

Life sciences crucial post-Brexit, says drug industry

Innovation will underpin the UK’s identity outside the European Union, according to the Association of British Pharmaceutical Industry.

The UK should support digital technologies and data to overcome health challenges and forge a new identity, Virginia Acha, executive director of research, medical and innovation at the ABPI, told delegates at an event on 27 April.

“We are at a critical point,” she said. “We’ve had an identity in terms of how we work as one of the EU nations. It is now imperative that the UK considers what it wants to be known as in the life sciences globally in 10 to 20 years’ time.”

This article is only available to Research Professional News subscribers or Pivot-RP users.

If you are a Research Professional News subscriber you can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.